Literature DB >> 11292337

The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition.

J G Heddle1, S J Blance, D B Zamble, F Hollfelder, D A Miller, L M Wentzell, C T Walsh, A Maxwell.   

Abstract

Microcin B17 is a 3.1-kDa bactericidal peptide; the putative target of this antibiotic is DNA gyrase. Microcin B17 has no detectable effect on gyrase-catalysed DNA supercoiling or relaxation activities in vitro and is unable to stabilise DNA cleavage in the absence of nucleotides. However, in the presence of ATP, or the non-hydrolysable analogue 5'-adenylyl beta,gamma-imidodiphosphate, microcin B17 stabilises a gyrase-dependent DNA cleavage complex in a manner reminiscent of quinolones, Ca(2+), or the bacterial toxin CcdB. The pattern of DNA cleavage produced by gyrase in the presence of microcin B17 is different from that produced by quinolones and more closely resembles Ca(2+)-mediated cleavage. Several gyrase mutants, including well-known quinolone-resistant mutants, are cross resistant to microcin-induced DNA cleavage. We suggest that microcin exerts its effects through a mechanism that has similarities to those of both the bacterial toxin CcdB and the quinolone antibacterial agents. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292337     DOI: 10.1006/jmbi.2001.4562

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  47 in total

1.  GyrI: a counter-defensive strategy against proteinaceous inhibitors of DNA gyrase.

Authors:  Monalisa Chatterji; Valakunja Nagaraja
Journal:  EMBO Rep       Date:  2002-02-15       Impact factor: 8.807

2.  In vitro characterization of DNA gyrase inhibition by microcin B17 analogs with altered bisheterocyclic sites.

Authors:  D B Zamble; D A Miller; J G Heddle; A Maxwell; C T Walsh; F Hollfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

Review 3.  A Toxic Environment: a Growing Understanding of How Microbial Communities Affect Escherichia coli O157:H7 Shiga Toxin Expression.

Authors:  Erin M Nawrocki; Hillary M Mosso; Edward G Dudley
Journal:  Appl Environ Microbiol       Date:  2020-11-24       Impact factor: 4.792

4.  Mechanism of bactericidal activity of microcin L in Escherichia coli and Salmonella enterica.

Authors:  Natacha Morin; Isabelle Lanneluc; Nathalie Connil; Marie Cottenceau; Anne Marie Pons; Sophie Sablé
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

5.  An Escherichia coli-based bioengineering strategy to study streptolysin S biosynthesis.

Authors:  Andrew L Markley; Emily R Jensen; Shaun W Lee
Journal:  Anal Biochem       Date:  2011-09-22       Impact factor: 3.365

6.  Pentapeptide repeat proteins.

Authors:  Matthew W Vetting; Subray S Hegde; J Eduardo Fajardo; Andras Fiser; Steven L Roderick; Howard E Takiff; John S Blanchard
Journal:  Biochemistry       Date:  2006-01-10       Impact factor: 3.162

7.  Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase.

Authors:  John H Tran; George A Jacoby; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 8.  How nature morphs peptide scaffolds into antibiotics.

Authors:  Elizabeth M Nolan; Christopher T Walsh
Journal:  Chembiochem       Date:  2009-01-05       Impact factor: 3.164

9.  Hydroxyl radicals are involved in cell killing by the bacterial topoisomerase I cleavage complex.

Authors:  I-Fen Liu; Thirunavukkarasu Annamalai; Jeanette H Sutherland; Yuk-Ching Tse-Dinh
Journal:  J Bacteriol       Date:  2009-06-12       Impact factor: 3.490

10.  Isolation and structure determination of new linear azole-containing peptides spongiicolazolicins A and B from Streptomyces sp. CWH03.

Authors:  Mana Suzuki; Hisayuki Komaki; Issara Kaweewan; Hideo Dohra; Hikaru Hemmi; Hiroyuki Nakagawa; Hideki Yamamura; Masayuki Hayakawa; Shinya Kodani
Journal:  Appl Microbiol Biotechnol       Date:  2020-11-20       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.